On February 15, a delegation including Tess Mak, Regional Director of AIA Group (a Fortune 500 company); Zeng Xiangbin from Dingrui Jinying Group; Wang Xiaodong, Executive Vice President of the China Sichuan Entrepreneurs Association and Founder of Jixiang Holdings Group; and Yi Long, Secretary-General of the All-American Hunan Chamber of Commerce and Founder/CEO of Shuihan Capital, visited Shenzhen Cell Valley. They were warmly received by our Chairman, Professor Shi Yuanyuan; Chief Scientist, Professor Wang Jianxun; Deputy General Manager Tang Xiaomeng; Chief Medical Advisor Dr. David Jin; Director of the General Manager's Office Wei Zheng; Executive Assistant to the Chairman Fu Yuchen; Head of Marketing Sun Rui; and Director of the General Affairs Office Wang Lu.

Accompanied by Professor Shi Yuanyuan, the visiting guests toured the Shenzhen Cell Valley Smart Exhibition Hall, where they gained a detailed understanding of the company's development history, core technologies, and research achievements. They subsequently visited the production workshops and R&D laboratories, gaining a more intuitive understanding of the operational workflows, production processes, and quality management systems.

During the symposium, Chairman Shi Yuanyuan first extended a warm welcome to the guests and provided a detailed introduction to the company's core technological advantages. He emphasized that Shenzhen Cell Valley possesses a comprehensive production and quality control system and has been continuously deepening its expertise in both genetically modified and non-genetically modified cell therapy technologies, aiming to contribute to the cause of human health. Professor Shi further elaborated on the important roles of NK cells, stem cells, and exosomes in driving the development of the medical and healthcare industry. He noted that NK cells are the body's primary "warriors" responsible for killing abnormal cells such as aging cells, virus-infected cells, and tumor cells; Mesenchymal Stem Cells (MSCs) not only possess multipotent differentiation potential but are also amenable to exogenous gene transfection with efficient and long-term expression; and exosomes, as important carriers of intercellular information transfer, offer therapeutic effects including immunomodulation, anti-inflammation, anti-fibrosis, inhibition of oxidative stress, and enhancement of angiogenesis. Following this, Chairman Shi shared insights on policy expectations and industry development trends. He stated that as the country attaches increasing importance to the "Great Health" industry, policy support will continue to strengthen, providing a favorable external environment for the R&D and application of cell therapy technologies.

Discussing cooperation with Hong Kong, Chairman Shi remarked that Shenzhen and Hong Kong are geographically close and share cultural affinities, with a broad foundation for collaboration in technology, finance, and healthcare. Shenzhen Cell Valley places great importance on cooperation and exchange with relevant Hong Kong institutions. He revealed that Shenzhen Cell Valley is currently establishing a subsidiary, "Deep Harbour Cell Valley," in the Qianhai Free Trade Zone, specifically targeting business in the Greater Bay Area, particularly Hong Kong. This initiative aims to promote the R&D and application of cell therapy technologies and foster the synergistic development of the health industries in both regions through closer and more targeted cooperation mechanisms.

Tess Mak, Director at AIA, introduced AIA's insurance services for high-net-worth individuals as Asia's largest life insurance group and expressed a desire to further deepen cooperation with medical institutions and enterprises in mainland China, particularly in Shenzhen. Director Mak stated that AIA looks forward to in-depth collaboration with Shenzhen Cell Valley to provide more advanced and effective healthcare services to its group clients. Other guests also spoke, engaging in in-depth discussions on how to strengthen cooperation between Shenzhen and Hong Kong in the health industry and promote the R&D and application of cell therapy technologies. Attendees unanimously agreed that this visit and exchange not only deepened mutual understanding and trust but also laid a solid foundation for future collaboration.

This interaction between Shenzhen and Hong Kong enterprises not only demonstrated Shenzhen Cell Valley's leading position and influence in the Great Health industry but also injected new vitality into cooperation and exchange between the two regions in this field. In the future, Shenzhen Cell Valley will continue to leverage its advantages and explore innovation, committed to making greater contributions to the cause of human health.